Corporate Satellite Symposia and Education Theater Schedule

Learning Objectives:

1. Summarize the unmet needs of children with VWD, discuss the potential benefits of prophylaxis in this population, when to initiate prophylaxis, and explore why it is underused.
2. Discuss recent data from clinical trials in children with VWD, demonstrating the benefits of prophylaxis for bleed control.

Faculty:

• Veronica Flood, MD, Versiti Blood Research Institute, Milwaukee, WI
• Fernando Corrales-Medina, MD, University of Miami, Miami, Florida
• Robert F. Sidonio, MD, Emory University School of Medicine, Atlanta, Georgia

This non-CME symposium is supported by Octapharma USA.

Asparaginase therapies are a cornerstone treatment component of chemotherapy regimens for pediatric and adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL). The clinical benefits derived from inclusion of asparaginase therapies is well established, and recent data and FDA approvals for asparaginase products with differing formulations and safety profiles are expanding treatment options for patients with ALL. Notably, the recent the FDA approval and updated safety labeling for asparaginase erwinia chrysanthemi offers clinical benefits of novel dosing regimens, and provides a reliable treatment option for affected patients faced not only with the barrier of hypersensitivity but also with the manufacturing issues that have plagued native asparaginase E chrysanthemi (Erwinaze/Erwinase) and led to global shortages.

However, the optimal use of asparaginase therapy in pediatric and AYA patients with ALL is not without its challenges. The complexity of ALL requires a nuanced understanding of disease progression, and approach to treatment selection after hypersensitivity reactions to Escherichia coli–derived L-asparaginases. Furthermore, HCPs must be aware of strategies to mitigate treatment interruptions while mitigating serious toxicities associated with asparaginase therapy - which is critical to optimize patient outcomes. Lastly, in an evolving treatment landscape of ALL, updated therapeutic regimens and treatment guidelines including the emergence of immune-targeted therapies, pose challenges in treatment sequencing and understanding the place in therapy for asparaginase therapies.

Learning Objectives:

1. Discuss current efficacy evidence and unmet needs related to the optimized use of asparaginase in pediatric ALL, including the role of novel Erwinia asparaginase compounds
2. Devise strategies to address therapeutically relevant considerations related to asparaginase use for pediatric ALL such as appropriate dosing, pre-empting truncation/discontinuation, and drug-related toxicity
3. Implement monitoring protocols to identify hypersensitivity, silent inactivation, or toxicity in pediatric ALL and increase completion rates of asparaginase treatment
4. Evaluate current clinical evidence and expert recommendations for implementing pediatric-inspired therapeutic regimens for ALL into treatment plans for adolescents and young adults, understanding the place in therapy of asparaginase regimens in an evolving clinical landscape

This CME symposium is provided by Clinical Care Options, LLC. Supported by an educational grant from Jazz Pharmaceuticals, Inc.

Platelet transfusions are the second most commonly prescribed blood product for pediatric patients. The risks of platelet transfusions include acute transfusion reactions, transfusion-transmitted infection (TTI), and transfusion-associated graft-versus-host disease (TA-GVHD). Furthermore, pediatric patients have been demonstrated to be more susceptible to acute transfusion reactions compared to adults. Pathogen reduction (PR) of platelet components (PC) with amotosalen-UVA is designed to mitigate the risks of TTI and TA-GVHD, but clinical data on transfusion reactions for pediatric patients are limited. Dr. Bryce Pasko and Dr. Samantha Phou of Phoenix Children’s Hospital will present findings from a recent retrospective study that analyzed transfusion reactions over two 30-month periods before and after the implementation of PR-platelets. This study provides insight into the safety profile of PR-platelets in pediatric patients and their impact on transfusion-related adverse events.

Faculty:

• Bryce Pasko, MD, Phoenix Children’s Hospital
• Samantha Phou, MD, Phoenix Children’s Hospital

This educational theater is supported by Cerus Corporation

This educational theater is supported by Y-mAbs Therapeutics, Inc